ADIL ADIAL PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 1513525 · EDGAR
- Bought, last 12 months
- $106.3K 3 purchases by 1 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 59 since 2021-10-06, latest 2026-09-21 19:25
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Coastlands Capital LP | 10% | $106.3K | — |
| Shah Vinay | CFO | — | — |
| Davidson Matt | Chief Development Off, Dir | — | — |
| Gilliland Robertson H. | Dir | — | — |
| Schuyler Kevin | Dir | — | — |
| Goodman Tony | COO, Dir | — | — |
| Claiborne Cary J | CEO, Dir | — | — |
Transactions 24
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-07-16 17:08 | 2026-07-14+ | ADIL | Coastlands Capital LP | 10% | P - Purchase | $2.69 | +3,233 | 388.3K | +0.8% | +$8,691 |
| MI | 2026-07-13 10:30 | 2026-07-09+ | ADIL | Coastlands Capital LP | 10% | P - Purchase | $2.78 | +11.8K | 385.1K | +3% | +$32.6K |
| I | 2026-07-01 10:30 | 2026-06-29 | ADIL | Coastlands Capital LP | 10% | P - Purchase | $2.60 | +25.0K | 373.3K | +7% | +$65.0K |
| DM | 2026-06-16 06:36 | 2026-06-11+ | ADIL | Davidson Matt | Chief Development Off, Dir | A - Grant | $0.00 | +295.9K | 1,822 | New | $0 |
| DMI | 2026-06-16 06:36 | 2026-06-11 | ADIL | Davidson Matt | Chief Development Off, Dir | A - Grant | — | +3,528 | 1,923 | New | — |
| 2026-04-09 17:00 | 2026-04-07 | ADIL | Goodman Tony | COO, Dir | A - Grant | $0.00 | +26.5K | 26.5K | +203,923% | $0 | |
| 2026-04-09 17:00 | 2026-04-07 | ADIL | Schuyler Kevin | Dir | A - Grant | $0.00 | +9,185 | 9,213 | +32,804% | $0 | |
| 2026-04-09 17:00 | 2026-04-07 | ADIL | Shah Vinay | CFO | A - Grant | $0.00 | +17.3K | 17.3K | New | $0 | |
| 2026-04-09 17:00 | 2026-04-07 | ADIL | Gilliland Robertson H. | Dir | A - Grant | $0.00 | +9,185 | 9,185 | New | $0 | |
| 2026-04-09 17:00 | 2026-04-07 | ADIL | Claiborne Cary J | CEO, Dir | A - Grant | $0.00 | +38.0K | 40.4K | +1,562% | $0 | |
| 2023-10-03 | 2023-09-29 | ADIL | Schuyler Kevin | Dir | P - Purchase | $2.74 | +700 | 700 | New | +$1,918 | |
| D | 2023-05-25 | 2023-05-23 | ADIL | Claiborne Cary J | CEO, Dir | A - Grant | $0.00 | +420.0K | 1.52M | +38% | $0 |
| D | 2023-05-25 | 2023-05-23 | ADIL | Truluck Joseph | CFO | A - Grant | $0.00 | +157.5K | 265.1K | +146% | $0 |
| D | 2023-05-25 | 2023-05-23 | ADIL | Stilley William B. III | Dir | A - Grant | $0.00 | +240.8K | 1.26M | +24% | $0 |
| 2023-01-03 | 2022-12-30 | ADIL | Stilley William B. III | Dir | D - Sale to Iss | $0.00 | -166.7K | 1.02M | -14% | $0 | |
| M | 2022-09-20 | 2022-09-19+ | ADIL | Claiborne Cary J | CEO, Dir | A - Grant | $0.4225 | +100.0K | 1.02M | +11% | +$42.2K |
| 2022-08-22 | 2022-08-18 | ADIL | Claiborne Cary J | CEO | A - Grant | $0.00 | +1.00M | 1.00M | New | $0 | |
| 2022-02-25 | 2022-02-23 | ADIL | Stilley William B. III | CEO, Dir | A - Grant | $0.00 | +250.0K | 1.19M | +27% | $0 | |
| 2022-01-03 | 2021-12-30 | ADIL | Newman James W. Jr. | Dir | P - Purchase | $2.66 | +10.0K | 20.0K | +100% | +$26.6K | |
| MI | 2022-01-03 | 2021-12-30 | ADIL | Newman James W. Jr. | Dir | P - Purchase | $2.71 | +15.0K | 34.6K | +76% | +$40.7K |
| D | 2021-12-23 | 2021-12-23 | ADIL | Schuyler Kevin | Dir, 10% | G - Gift | $0.00 | -313.0K | 0 | -100% | $0 |
| M | 2021-12-01 | 2021-11-29+ | ADIL | Stilley William B. III | CEO, Dir, 10% | P - Purchase | $2.67 | +20.6K | 927.0K | +2% | +$55.0K |
| I | 2021-11-30 | 2021-11-26 | ADIL | Newman James W. Jr. | Dir | P - Purchase | $2.85 | +10.0K | 34.5K | +41% | +$28.5K |
| DI | 2021-10-06 | 2021-10-04 | ADIL | Johnson Bankole A. | Chief Medical Off | S - Sale | — | -200.0K | 148.2K | -57% | — |
Purchase Sale Sale after option exercise All abbreviations